A Phase 3 interventional study of Synflorix and Infanrix hexa in Infections, Rotavirus, sponsored by GlaxoSmithKline. Completed at 3 sites in Taiwan. Open to participants aged 6 Weeks to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-08.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Rotavirus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rotavirus Infections · GlaxoSmithKline.
Among the 61 studies in Rotavirus Infections by GlaxoSmithKline, this one is the 30th largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2007, is one of 23 in phase 3, and was the 28th registered.
104 studies on the registry are indexed under Rotavirus Infections; 3 are open to participants now.
Browse Rotavirus Infections studies →None of the 61 studies in Rotavirus Infections by GlaxoSmithKline is open now. The open studies under Rotavirus Infections, anywhere →
Of the 3 Rotavirus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 6 Weeks to 8 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is below the median of 403 across 69 interventional studies indexed under Rotavirus Infections.
Median enrollment 507 across the 38 interventional studies, 522 across the 23 observational. Of the 59 that completed or were terminated, 21 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 61 studies in Rotavirus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of Taiwanese infants with pneumococcal conjugate vaccine GSK 1024850A co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined vaccine and rotavirus vaccine in children during the first 6 months of life.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.
Biological: Synflorix · Biological: Infanrix hexa · Biological: Rotarix
Intramuscular injection, 3 doses.
Also known as: Pneumococcal conjugate vaccine GSK1024850A
Intramuscular injection, 3 doses.
Also known as: DTPa-HBV-IPV/Hib
Oral, 2 doses.
Also known as: HRV vaccine
Concentration of Anti-Protein D Antibodies
Concentrations are given as geometric mean concentrations (GMC) and expressed in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).
Time frame: One month after the third dose
Concentration of Anti-Pneumococcal Antibodies
Concentrations are given as geometric mean titers (GMC) and expressed in microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Time frame: One month after the third dose
Number of Subjects With Anti-Protein D Antibody Concentrations Above the Cut-Off Value
Anti-protein D antibody cut-off value assessed was greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).
Time frame: Before the first dose (pre) and one month after (post) the third dose
Number of Subjects With Vaccine Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value
Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (μg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Time frame: Before the first dose (pre) and one month after (post) the third dose
Number of Subjects With Cross-Reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value
Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL).
Time frame: One month after the third dose
Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes Above the Cut-Off Value
Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was greater than or equal to 1:8 titer.
Time frame: One month after the third dose
Number of Subjects With Opsonophagocytic Activity Against Cross-Reactive Pneumococcal Serotypes Above the Cut-Off Value
Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was greater than or equal to 1:8 titer.
Time frame: One month after the third dose
Number of Subjects With Anti-Polyribosyl-Ribitol Phosphate Antibody Concentrations Above the Cut-Off Value
Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was greater than or equal to 0.15 microgram per milliliter (μg/mL).
Time frame: One month after the third dose
Number of Subjects With Anti-Diphteria and Anti-Tetanus Toxoids Antibody Concentrations Above the Cut-Off Value
Anti-diphteria and anti-tetanus toxoids antibody cut-off values assessed were greater than or equal to 0.10 International Units per milliliter (IU/mL).
Time frame: One month after the third dose
Number of Subjects With Anti-Pertussis (PT), Anti-Filamentous Hemagglutinin (FHA) and Anti-Pertactin (PRN) Antibody Concentrations Above the Cut-Off Value
Anti-PT, anti-FHA and anti-PRN cut-off values assessed were greater than or equal to 5 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).
Time frame: One month after the third dose
Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-Off Value
Anti-HBs antibody cut-off value assessed was greater than or equal to 10 milli-International Units per milliliter (mIU/mL).
Time frame: One month after the third dose
Number of Subjects With Anti-Poliovirus 1, 2 and 3 Antibody Titers Above the Cut-Off Value
Anti-poliovirus 1, 2 and 3 antibody cut-off value assessed was greater than or equal to 1:8 titer.
Time frame: One month after the third dose
Number of Subjects With Anti-rotavirus Immunoglobulin A Antibody Concentrations Above the Cut-Off Value
Anti-rotavirus IgA antibody cut-off value assessed was greater than or equal to 20 Units per milliliter (U/mL).
Time frame: Four months after the administration of the second dose of Rotarix™ vaccine
Number of Subjects Reporting Solicited Symptoms
Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include diarrhoea, drowsiness, fever, irritability, loss of appetite, and vomiting
Time frame: During the 4-day (Day 0-3) period after each dose
Number of Subjects Reporting Unsolicited Adverse Events (AE)
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
Time frame: During the 31-day (Day 0-30) period after each dose
Number of Subjects Reporting Serious Adverse Events (SAE)
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
Time frame: Up to one month after the third dose
| Milestone | Synflorix Group |
|---|---|
| Started | 230 |
| Completed | 229 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Concentrations are given as geometric mean concentrations (GMC) and expressed in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).
| EL.U/mL | Synflorix Group |
|---|---|
| Concentration of Anti-Protein D Antibodies | 2277.6 (2048.7 to 2532.1) |
Concentrations are given as geometric mean titers (GMC) and expressed in microgram per milliliter (µg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
| µg/mL | Synflorix Group |
|---|---|
| Anti-1 | 2.92 (2.65 to 3.22) |
| Anti-4 | 3.79 (3.42 to 4.19) |
| Anti-5 | 4.50 (4.11 to 4.93) |
| Anti-6B | 1.69 (1.47 to 1.94) |
| Anti-7F | 4.07 (3.72 to 4.46) |
| Anti-9V | 3.90 (3.51 to 4.32) |
| Anti-14 | 5.69 (5.10 to 6.35) |
| Anti-18C | 7.28 (6.43 to 8.25) |
| Anti-19F | 8.04 (7.37 to 8.78) |
| Anti-23F | 2.81 (2.44 to 3.22) |
Anti-protein D antibody cut-off value assessed was greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).
| subjects | Synflorix Group |
|---|---|
| Pre (N=217) | 38 |
| Post (N=219) | 218 |
Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (μg/mL). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
| subjects | Synflorix Group |
|---|---|
| Anti-1 Pre (N=217) | 111 |
| Anti-1 Post (N=219) | 219 |
| Anti-4 Pre (N=217) | 85 |
| Anti-4 Post (N=219) | 219 |
| Anti-5 Pre (N=217) | 149 |
| Anti-5 Post (N=219) | 219 |
| Anti-6B Pre (N=217) | 107 |
| Anti-6B Post (N=219) | 215 |
| Anti-7F Pre (N=218) | 138 |
| Anti-7F Post (N=219) | 219 |
| Anti-9V Pre (N=218) | 123 |
| Anti-9V Post (N=219) | 219 |
| Anti-14 Pre (N=218) | 203 |
| Anti-14 Post (N=219) | 219 |
| Anti-18C Pre (N=219) | 153 |
| Anti-18C Post (N=219) | 219 |
| Anti-19F Pre (N=219) | 172 |
| Anti-19F Post (N=219) | 219 |
| Anti-23F Pre (N=219) | 91 |
| Anti-23F Post (N=219) | 216 |
Anti-pneumococcal antibody cut-off value assessed was 0.05 microgram per milliliter (µg/mL).
| subjects | Synflorix Group |
|---|---|
| Anti-6A (N=219) | 210 |
| Anti-19A (N=218) | 200 |
Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was greater than or equal to 1:8 titer.
| subjects | Synflorix Group |
|---|---|
| Opsono-1 (N=102) | 98 |
| Opsono-4 (N=103) | 103 |
| Opsono-5 (N=102) | 101 |
| Opsono-6B (N=102) | 89 |
| Opsono-7F (N=103) | 103 |
| Opsono-9V (N=98) | 98 |
| Opsono-14 (N=102) | 101 |
| Opsono-18C (N=101) | 99 |
| Opsono-19F (N=103) | 101 |
| Opsono-23F (N=102) | 98 |
Cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was greater than or equal to 1:8 titer.
| subjects | Synflorix Group |
|---|---|
| Opsono-6A | 87 |
| Opsono-19A | 38 |
Anti-polyribosyl-ribitol phosphate antibody cut-off value assessed was greater than or equal to 0.15 microgram per milliliter (μg/mL).
| subjects | Synflorix Group |
|---|---|
| Number of Subjects With Anti-Polyribosyl-Ribitol Phosphate Antibody Concentrations Above the Cut-Off Value | 58 |
Anti-diphteria and anti-tetanus toxoids antibody cut-off values assessed were greater than or equal to 0.10 International Units per milliliter (IU/mL).
| subjects | Synflorix Group |
|---|---|
| Anti-diphteria toxoid | 58 |
| Anti-tetanus toxoid | 58 |
Anti-PT, anti-FHA and anti-PRN cut-off values assessed were greater than or equal to 5 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter (EL.U/mL).
| subjects | Synflorix Group |
|---|---|
| Anti-PT (N=58) | 58 |
| Anti-FHA (N=58) | 58 |
| Anti-PRN (N=57) | 57 |
Anti-HBs antibody cut-off value assessed was greater than or equal to 10 milli-International Units per milliliter (mIU/mL).
| subjects | Synflorix Group |
|---|---|
| Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-Off Value | 32 |
Anti-poliovirus 1, 2 and 3 antibody cut-off value assessed was greater than or equal to 1:8 titer.
| subjects | Synflorix Group |
|---|---|
| Anti-poliovirus 1 | 44 |
| Anti-poliovirus 2 | 44 |
| Anti-poliovirus 3 | 44 |
Anti-rotavirus IgA antibody cut-off value assessed was greater than or equal to 20 Units per milliliter (U/mL).
| subjects | Synflorix Group |
|---|---|
| Number of Subjects With Anti-rotavirus Immunoglobulin A Antibody Concentrations Above the Cut-Off Value | 44 |
Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include diarrhoea, drowsiness, fever, irritability, loss of appetite, and vomiting
| subjects | Synflorix Group |
|---|---|
| Pain | 146 |
| Redness | 144 |
| Swelling | 139 |
| Diarrhoea | 7 |
| Drowsiness | 190 |
| Fever | 153 |
| Irritability | 203 |
| Loss of appetite | 159 |
| Vomiting | 55 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
| subjects | Synflorix Group |
|---|---|
| Number of Subjects Reporting Unsolicited Adverse Events (AE) | 95 |
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
| subjects | Synflorix Group |
|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAE) | 15 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Synflorix Group | — | — | 224/230 (97.4%) |
| Event | Synflorix Group |
|---|---|
| Urinary tract infectionInfections and infestations | 6/230 |
| BronchiolitisInfections and infestations | 4/230 |
| GastroenteritisInfections and infestations | 2/230 |
| PyrexiaGeneral disorders | 2/230 |
| Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders | 1/230 |
| BronchopneumoniaInfections and infestations | 1/230 |
| DehydrationMetabolism and nutrition disorders | 1/230 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/230 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 1/230 |
| EnterocolitisGastrointestinal disorders | 1/230 |
| Event | Synflorix Group |
|---|---|
| IrritabilityGeneral disorders | 203/230 |
| DrowsinessGeneral disorders | 190/230 |
| Loss of appetiteGeneral disorders | 159/230 |
| FeverGeneral disorders | 153/230 |
| PainGeneral disorders | 146/230 |
| RednessGeneral disorders | 144/230 |
| SwellingGeneral disorders | 139/230 |
| VomitingGeneral disorders | 55/230 |
| Upper respiratory tract infectionInfections and infestations | 54/230 |
| Age, Continuous(weeks) | Synflorix Group |
|---|---|
| Mean | 6.4 ± 0.60 |
| Sex: Female, Male(Participants) | Synflorix Group |
|---|---|
| Female | 115 |
| Male | 115 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Sep 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PHiD-CV vaccine · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · RIX4414 vaccine